GTM:NASDAQZoomInfo Technologies Inc. Analysis
Data as of 2026-09-04 - not real-time
$4.12
Latest Price
9/10Risk
Risk Level: High
Executive Summary
At $4.12, ZoomInfo Technologies Inc. shows no decisive moving-average alignment, leaving the trend neutral. It has gained 43.1% over the past 30 days. With RSI at 58.7 the momentum picture is neutral, alongside a bearish MACD signal. Price has been bracketed by support at $3.72 and resistance at $4.36.
On valuation the read is undervalued — earnings multiple of 3.7 versus a 32.9 sector average, below the peer group. Sell-side targets cluster 11.6% above the current quote.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 75.9%, a beta of 1.07 and a maximum drawdown of 78.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
On valuation the read is undervalued — earnings multiple of 3.7 versus a 32.9 sector average, below the peer group. Sell-side targets cluster 11.6% above the current quote.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 75.9%, a beta of 1.07 and a maximum drawdown of 78.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
Top Market Events
Robbins LLP Reminds GTM Investors of the Opportunity to Seek Appointment for Lead Plaintiff in the Class Action Against...GTM Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ZoomInfo Technologies Inc.Stockhouse1monClass Action Filed Against ZoomInfo Technologies Inc.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 5.98
- MACD momentum is negative
- 30-day price change of +43.1%
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 3.7 versus sector average of 32.9
- Trading below the 200-day average of 5.98
- Analyst targets imply +11.6% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 3.7 versus sector average of 32.9
- Negative profit margin of -43.0%
- Analyst targets imply +11.6% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth1.20%
Profit Margin-43.02%
P/E Ratio3.7
ROE-45.45%
ROA2.92%
Debt/Equity183.23
P/B Ratio1.5
Op. Cash Flow$439.3M
Free Cash Flow$356.5M
Industry P/E32.9
Technical Analysis
TrendNeutral
RSI58.7
Support$3.72
Resistance$4.36
MA 20$4.02
MA 50$3.48
MA 200$5.98
MACDBearish
VolumeDecreasing
Fear & Greed Index96.14
Valuation
Fair Value$11.59
Target Price$4.60
Upside/Downside11.58%
GradeUndervalued
TypeValue
Risk Assessment
Beta1.07
Volatility75.85%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.